OCGN - Ocugen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Malvern,
United States
Type: Equity
OCGN price evolution
OCGN
| (in millions $) | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $68.26 | $77.56 | $101.6 | $115 |
| Short term investments | $8.46 | $13.37 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $84.4 | $98.49 | $107.5 | $122.57 |
| Long term investments | ||||
| Property, plant & equipment | $7.95 | $9.96 | $4.52 | $3.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $11.9 | $10.14 | $8.74 | $7.52 |
| Total investments | $8.46 | $13.37 | ||
| Total assets | $96.3 | $108.63 | $116.24 | $130.09 |
| Current liabilities | ||||
| Accounts payable | $8.09 | $8.06 | $6.46 | $5.92 |
| Deferred revenue | ||||
| Short long term debt | $1.77 | $0.5 | $0.44 | $0.31 |
| Total current liabilities | $15.68 | $18.46 | $14.91 | $10.34 |
| Long term debt | $4.51 | $2.29 | $6.03 | $5.64 |
| Total noncurrent liabilities | $4.82 | $6.12 | $6.03 | $5.64 |
| Total debt | $6.28 | $6.37 | $6.47 | $5.96 |
| Total liabilities | $20.5 | $24.58 | $20.94 | $15.98 |
| Shareholders' equity | ||||
| Retained earnings | -$229.52 | -$213.02 | -$191.08 | -$169.16 |
| Other shareholder equity | $0.03 | $0.03 | $0.03 | $0.01 |
| Total shareholder equity | $75.8 | $84.05 | $95.3 | $114.11 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $77.56 | $95.11 | $24.19 | $7.6 |
| Short term investments | $13.37 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $98.49 | $102.65 | $25.88 | $15.77 |
| Long term investments | ||||
| Property, plant & equipment | $9.96 | $1.16 | $0.63 | $0.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $10.14 | $3.12 | $1.5 | $1.04 |
| Total investments | $13.37 | |||
| Total assets | $108.63 | $105.76 | $27.38 | $16.81 |
| Current liabilities | ||||
| Accounts payable | $8.06 | $2.31 | $0.4 | $1.9 |
| Deferred revenue | ||||
| Short long term debt | $0.5 | $0.36 | $0.28 | $0.17 |
| Total current liabilities | $18.46 | $7 | $3.61 | $4.54 |
| Long term debt | $2.29 | $2.94 | $2.21 | $1.24 |
| Total noncurrent liabilities | $6.12 | $2.94 | $2.21 | $1.25 |
| Total debt | $6.37 | $3.31 | $2.49 | $1.41 |
| Total liabilities | $24.58 | $9.94 | $5.83 | $5.79 |
| Shareholders' equity | ||||
| Retained earnings | -$213.02 | -$131.67 | -$73.3 | -$51.48 |
| Other shareholder equity | $0.03 | -$0.05 | -$0.05 | |
| Total shareholder equity | $84.05 | $95.82 | $21.55 | $11.02 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $9.56 | $17.21 | $15.62 | $9.01 |
| Selling, general & administrative | $8.19 | $6.94 | $7.5 | $10.56 |
| Total operating expenses | $17.75 | $24.15 | $23.12 | $19.57 |
| Operating income | -$17.75 | -$24.15 | -$23.12 | -$19.57 |
| Income from continuing operations | ||||
| EBIT | -$16.5 | -$21.94 | -$21.92 | -$19.47 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$16.5 | -$21.94 | -$21.92 | -$19.47 |
| Income (for common shares) | -$16.5 | -$21.94 | -$21.92 | -$19.47 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.04 | |||
| Cost of revenue | ||||
| Gross Profit | $0.04 | |||
| Operating activities | ||||
| Research & development | $49.76 | $35.11 | $6.35 | $8.09 |
| Selling, general & administrative | $35.11 | $22.92 | $7.97 | $6.08 |
| Total operating expenses | $84.87 | $58.03 | $21.33 | $14.16 |
| Operating income | -$84.87 | -$58.03 | -$21.28 | -$14.16 |
| Income from continuing operations | ||||
| EBIT | -$81.35 | -$58.34 | -$21.1 | -$18.47 |
| Income tax expense | -$0.05 | |||
| Interest expense | $0.08 | $0.72 | $1.77 | |
| Net income | ||||
| Net income | -$81.35 | -$58.37 | -$21.82 | -$20.24 |
| Income (for common shares) | -$81.35 | -$58.37 | -$34.37 | -$20.24 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$16.5 | -$21.94 | -$21.92 | -$19.47 |
| Operating activities | ||||
| Depreciation | $0.3 | $0.3 | $0.27 | $0.24 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.69 | $2.67 | $2.5 | $2.08 |
| Total cash flows from operations | -$18.24 | -$16.91 | -$14.3 | -$13.8 |
| Investing activities | ||||
| Capital expenditures | -$1.61 | -$2.02 | -$0.84 | -$1.37 |
| Investments | $5.05 | -$13.27 | $0.76 | |
| Total cash flows from investing | $3.44 | -$15.29 | -$0.08 | -$1.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.56 | $8.12 | $0.51 | $0.28 |
| Net borrowings | -$0.06 | $0.46 | ||
| Total cash flows from financing | $5.5 | $8.18 | $0.96 | $0.24 |
| Effect of exchange rate | -$0 | -$0.01 | $0.02 | $0.01 |
| Change in cash and equivalents | -$9.3 | -$24.04 | -$13.4 | -$14.92 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$81.35 | -$58.37 | -$21.82 | -$20.24 |
| Operating activities | ||||
| Depreciation | $1.07 | $0.59 | $0.29 | $0.31 |
| Business acquisitions & disposals | -$0.13 | -$2.33 | ||
| Stock-based compensation | $10.54 | $6.96 | $0.66 | $0.88 |
| Total cash flows from operations | -$60.08 | -$47.94 | -$14.71 | -$16.89 |
| Investing activities | ||||
| Capital expenditures | -$4.46 | -$0.94 | -$0.31 | -$0.03 |
| Investments | -$12.51 | |||
| Total cash flows from investing | -$16.97 | -$1.82 | -$0.31 | -$2.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $59.02 | $120.69 | $36.34 | $23.68 |
| Net borrowings | $0.46 | -$0.01 | -$4.73 | $1.38 |
| Total cash flows from financing | $59.48 | $120.68 | $31.61 | $25.07 |
| Effect of exchange rate | $0.03 | |||
| Change in cash and equivalents | -$17.55 | $70.92 | $16.6 | $5.82 |
News
|
Ocugen, Inc. (NASDAQ:OCGN): Is Breakeven Near?
Simply Wall St. via Yahoo Finance
1 Mar 2023
|
|
Philadelphia-area public companies lost $186B in value in 2022. These were the biggest winners and...
American City Business Journals
10 Jan 2023
|
|
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's...
Benzinga via Yahoo Finance
9 Jan 2023
|
|
Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study
Benzinga via Yahoo Finance
9 Jan 2023
|
|
Ocugen Inc. stock rises Friday, still underperforms market
Market Watch
6 Jan 2023
|
|
These 4 Stocks Have Tripled During A Lousy Year
Forbes
8 Nov 2022
|
|
Ocugen: Q3 Earnings Snapshot
The News-Times
8 Nov 2022
|
|
Ocugen Inc. stock outperforms competitors on strong trading day
Market Watch
8 Nov 2022
|
|
Ocugen, Inc.'s (NASDAQ:OCGN) largest shareholders are individual investors with 58% ownership,...
Simply Wall St. via Yahoo Finance
7 Nov 2022
|
|
Stocks to watch: AAPL, OCGN, SMTS, PATH
Seeking Alpha
28 Sep 2022
|
Fundamentals
| Market cap | $106.87M |
|---|---|
| Enterprise value | $44.89M |
| Shares outstanding | 226.43M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$78.71M |
| EBIT | -$79.83M |
| Net Income | -$79.83M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.34 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.57 |
| EV/EBIT | -0.56 |
| P/S ratio | N/A |
| P/B ratio | 1.41 |
| Book/Share | 0.33 |
| Cash/Share | 0.30 |
| EPS | -$0.35 |
|---|---|
| ROA | -70.76% |
| ROE | -86.47% |
| Debt/Equity | 0.29 |
|---|---|
| Net debt/EBITDA | 0.61 |
| Current ratio | 5.38 |
| Quick ratio | 5.38 |